bioXXmed AG Statistics

Total Valuation

bioXXmed AG has a market cap or net worth of EUR 72,724. The enterprise value is 130,724.

Market Cap	72,724
Enterprise Value	130,724

Important Dates

The next estimated earnings date is Friday, December 19, 2025.

Earnings Date	Dec 19, 2025
Ex-Dividend Date	n/a

Share Statistics

bioXXmed AG has 1.36 million shares outstanding. The number of shares has increased by 164.59% in one year.

Current Share Class	1.36M
Shares Outstanding	1.36M
Shares Change (YoY)	+164.59%
Shares Change (QoQ)	-38.35%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	n/a

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	3.55
PB Ratio	1.15
P/TBV Ratio	1.15
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-0.15
EV / Sales	6.38
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.06, with a Debt / Equity ratio of 2.14.

Current Ratio	2.06
Quick Ratio	1.39
Debt / Equity	2.14
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-256.18

Financial Efficiency

Return on equity (ROE) is -1,042.83% and return on invested capital (ROIC) is -314.08%.

Return on Equity (ROE)	-1,042.83%
Return on Assets (ROA)	-164.10%
Return on Invested Capital (ROIC)	-314.08%
Return on Capital Employed (ROCE)	-320.22%
Revenue Per Employee	20,493
Profits Per Employee	-890,907
Employee Count	1
Asset Turnover	0.07
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -98.00% in the last 52 weeks. The beta is 1.19, so bioXXmed AG's price volatility has been higher than the market average.

Beta (5Y)	1.19
52-Week Price Change	-98.00%
50-Day Moving Average	0.13
200-Day Moving Average	0.53
Relative Strength Index (RSI)	47.36
Average Volume (20 Days)	189

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, bioXXmed AG had revenue of EUR 20,493 and -890,907 in losses. Loss per share was -0.66.

Revenue	20,493
Gross Profit	20,493
Operating Income	-768,534
Pretax Income	-890,907
Net Income	-890,907
EBITDA	-641,076
EBIT	-768,534
Loss Per Share	-0.66

Full Income Statement

Balance Sheet

The company has 77,000 in cash and 135,000 in debt, giving a net cash position of -58,000 or -0.04 per share.

Cash & Cash Equivalents	77,000
Total Debt	135,000
Net Cash	-58,000
Net Cash Per Share	-0.04
Equity (Book Value)	63,000
Book Value Per Share	0.05
Working Capital	70,000

Full Balance Sheet

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	100.00%
Operating Margin	-3,750.23%
Pretax Margin	-4,347.37%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

bioXXmed AG does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-164.59%
Shareholder Yield	-164.59%
Earnings Yield	-1,225.05%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on August 12, 2024. It was a reverse split with a ratio of 0.1.

Last Split Date	Aug 12, 2024
Split Type	Reverse
Split Ratio	0.1

Scores

bioXXmed AG has an Altman Z-Score of -205.73 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-205.73
Piotroski F-Score	1